Articles related to CARDIOVASCULAR RISK

Baxdrostat significantly reduced seated systolic blood pressure compared to placebo in 796 patients, with placebo-adjusted reductions of 9.8 mmHg and 8.7 mmHg at the 2 mg and 1 mg doses respectively, without impacting cortisol levels.

Rare lipid disorders can drive extreme cholesterol abnormalities and early disease, making clinical recognition critical when lipid patterns don’t fit typical cardiology presentations.

In a 10‑year cohort study, adults with irregular bedtimes and short sleep duration had nearly double the risk of heart attack or stroke, suggesting sleep timing may be a meaningful cardiovascular risk marker.

Small studies suggest NMN supplementation may slightly affect blood pressure, but observed changes are modest and far less impactful than established therapies.

The findings support, whenever possible, prioritizing higher-intensity activities in clinical and public health interventions aimed at preventing non-communicable diseases.

Patient history and self-perception are valuable factors, but should never confirm a diagnosis and must be weighed against objective findings.